Our website uses its own and third parties cookies for a high level of user-friendliness. If you continue to browse and  use this website we will assume that you agree with the policies.

R&D

TheraYAP A tailored and rational approach for treating cancer patients with a YAP-TEAD inhibitor

The main goal of the project is to deliver an innovative and effective cancer drug to patients. We will also develop a companion diagnostic tool to allow the early identification of patients that will benefit from this novel treatment. The ultimate goal is to reduce the burden of EU healthcare providing more efficacious treatment as a stand-alone agent or in combination with standard of care drugs.

The first sub-objective of the project is to focus the study of the efficacy of compounds that have shown a higher cytotoxicity in screening tests using cell line libraries in three specific tumor types: NSCLC, TNBC and malignant mesothelioma. These three tumor types, in which YAP1 alteration has been described, belong to the group of tumors with a lower survival rate at 5 years, so possible advances in limited treatment options are of vital importance for patients.

The second sub-objective of the project is the development of diagnostic tools for an optimal selection of patients eligible for therapy. To this end, efforts will be focused on obtaining genomic signatures related to a greater sensitivity or resistance to the compounds tested, and the validation of a new antibody for the detection and localization of YAP1 by IHC and / or IF. In both cases the final objective will be to obtain of a Companion Kit that allows the identification of the patients that can benefit from the therapy through the use of validated methods and guides of interpretation of the results for the analysis of the alterations of YAP.

In order to successfully achieve the goals of the Project, a consortium between three European SMEs has been constituted. This consortium combines Inventiva’s expertise in drug discovery, XenTech’s skills in PDX-based anticancer drug efficacy studies and biomarker identification and Atrys’s expertise in the field of inmunohistochemistry and inmunofluorescence.

EUROSTARS Program, cofunded by EUREKA and the European Union, which stands out for its support to SMEs with a clear innovative approach in the development of international R&D projects which are also oriented to the market.

This project has received funding from the joint Eurostars-2 program with co-financing from the CDTI and the European Union's Horizon 2020 Research and Innovation Framework Program.

2016-2019

 

 

 

 

2016-2018